How do you choose between blinatumomab and CAR-T cell therapy for relapsed or refractory pre B-ALL?

Many of the cellular therapy products are limited in indication which can help with making the decision, as well as the plan to go to transplant or not. Blinatumomab would have to be consolidated with HSCT while CAR-T can be curative in about 50% of patients without consolidative HSCT, which would b...

We typically select blinatumomab for patients with low-burden marrow relapse who are transplant-naive, have no extramedullary disease, and have an available donor for hematopoietic stem cell transplantation. It’s particularly used as a bridge to curative transplant since it’s available off the shelf...

The decision to use blinatumomab vs CAR-T cell therapy depends largely on disease burden and whether the destination consolidation is allogeneic HSCT or CAR-T cell therapy itself. For patients for whom the goal is allogeneic HSCT, I would treat with blinatumomab alone for low-burden disease or inotu...